| Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade H Grauers Wiktorin, MS Nilsson, R Kiffin, FE Sander, B Lenox, A Rydström, ... Cancer Immunology, Immunotherapy 68 (2), 163-174, 2019 | 83 | 2019 |
| NOX2‐derived reactive oxygen species in cancer H Grauers Wiktorin, E Aydin, K Hellstrand, A Martner Oxidative medicine and cellular longevity 2020 (1), 7095902, 2020 | 54 | 2020 |
| Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase A Martner, HG Wiktorin, B Lenox, F Ewald Sander, E Aydin, J Aurelius, ... The Journal of Immunology 194 (10), 5014-5021, 2015 | 50 | 2015 |
| NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease E Aydin, A Hallner, H Grauers Wiktorin, A Staffas, K Hellstrand, A Martner Oncogene 38 (9), 1534-1543, 2019 | 33 | 2019 |
| Anti-leukemic properties of histamine in monocytic leukemia: the role of NOX2 R Kiffin, H Grauers Wiktorin, MS Nilsson, J Aurelius, E Aydin, B Lenox, ... Frontiers in Oncology 8, 218, 2018 | 30 | 2018 |
| Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity S Einarsdottir, A Martner, J Waldenström, M Nicklasson, J Ringlander, ... Blood Advances 6 (9), 2723-2730, 2022 | 24 | 2022 |
| Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination S Al-Dury, J Waern, J Waldenström, M Alavanja, HH Saed, A Törnell, ... JHEP Reports 4 (7), 100496, 2022 | 22 | 2022 |
| Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation S Einarsdottir, A Martner, M Nicklasson, HG Wiktorin, M Arabpour, ... Haematologica 107 (6), 1479, 2022 | 21 | 2022 |
| Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance H Grauers Wiktorin, E Aydin, K Christenson, N Issdisai, FB Thorén, ... Oncoimmunology 10 (1), 1944538, 2021 | 16 | 2021 |
| Role of NOX2 for leukaemic expansion in a murine model of BCR‐ABL1+ leukaemia. H Grauers Wiktorin, T Nilsson, E Aydin, K Hellstrand, L Palmqvist, ... British journal of haematology 182 (2), 2018 | 12 | 2018 |
| Rapid cytokine release assays for analysis of severe acute respiratory syndrome coronavirus 2–specific T cells in whole blood A Törnell, H Grauers Wiktorin, J Ringlander, M Arabpour, MR Nilsson, ... The Journal of Infectious Diseases 226 (2), 208-216, 2022 | 10 | 2022 |
| Transient and durable T cell reactivity after COVID-19 A Martner, H Grauers Wiktorin, A Törnell, J Ringlander, M Arabpour, ... Proceedings of the National Academy of Sciences 119 (30), e2203659119, 2022 | 9 | 2022 |
| An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis M Arabpour, S Paul, H Grauers Wiktorin, M Kaya, R Kiffin, N Lycke, ... Oncoimmunology 11 (1), 2115618, 2022 | 6 | 2022 |
| COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation HG Wiktorin, S Einarsdottir, A Törnell, M Arabpour, N Issdisai, ... Haematologica 107 (10), 2492, 2022 | 3 | 2022 |
| Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia HG Wiktorin, T Nilsson, A Jansson, L Palmqvist, A Martner Experimental Hematology & Oncology 5, 1-7, 2015 | 3 | 2015 |
| Presence of MDSC associates with impaired antigen-specific T cell reactivity following COVID-19 vaccination in cirrhotic patients A Törnell, E Blick, S Al-Dury, H Grauers Wiktorin, J Waern, J Ringlander, ... Frontiers in Immunology 14, 1287287, 2023 | 2 | 2023 |
| Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination A Törnell, HG Wiktorin, J Ringlander, M Arabpour, S Nilsson, M Lindh, ... Clinical Immunology 248, 109248, 2023 | 2 | 2023 |
| Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines S Paul, M Kaya, O Johnsson, H Grauers Wiktorin, A Törnell, M Arabpour, ... Human Vaccines & Immunotherapeutics 21 (1), 2455240, 2025 | | 2025 |
| 613 Tumor stroma inflammation and a systemic inflammatory response confirmed in patients treated with intratumoral tumor microenvironment gene engineering (LOKON002 trial) J Wenthe, A Hahn, HG Wiktorin, LC Sandin, CB Nordström, A Sundin, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma O Hamid, V Rydén, I Mehmi, D Wang, M Patel, J Krause, LC Sandin, ... Annals of Oncology 35, S674, 2024 | | 2024 |
Anna MartnerUniversity of Gothenburg在 gu.se 的电子邮件经过验证
